Skip to main content
OpenTrials
Completed

NCT Number: NCT07234318

A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study

The FOCUS study aims to evaluate the clinical efficacy of 0.1% cyclosporine eye drops solution (Vevizye®, Laboratoires THEA) in patients with moderate to severe dry eye disease characterized by ocular surface inflammation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Medical University of Vienna

Vienna, 1090, Austria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • No patients with other ophthalmic diseases than DED
  • Chronic dry eye defined as longer than six months since diagnosis
  • OSDI score > 22
  • Conjunctival Hyperemia ≥ Grade 3 (Efron Scale)
  • Current use of tear substitutes for at least 3 months not to be considered as sufficient by the investigator/treating physician
  • Need to add cyclosporine eye drops to tear substitutes as judged by the investigator/treating physician

Exclusion criteria

Ophthalmic exclusion criteria

  • Far best corrected visual acuity < 1/10
  • Severe Dry Eye associated with:
  • Eyelid malposition
  • Stevens Johnson Syndrome
  • Corneal dystrophy
  • Ocular neoplasia
  • Filamentous keratitis
  • Corneal neovascularisation
  • Orbital radiotherapy
  • Dry eye related to Graft Versus Host Disease (GVHD)
  • History of any of the following within last 3 months:
  • Systemic treatment of dry eye
  • Systemic treatment of Meibomian Gland Dysfunction (MGD)
  • Isotretinoïde,
  • Cyclosporine,
  • Tacrolimus, Siromilus, Pimecrolimus
  • Punctual plugs
  • History of any of the following within previous six months:
  • ocular trauma
  • ocular infection, Ocular allergy
  • History of any of the following within last 12 months:
  • inflammatory corneal ulcer
  • Herpetic eye infection
  • or uveitis
  • Ocular surgery

Systemic / non ophthalmic exclusion criteria:

•Known hypersensitivity to any of the components of the medical product under investigation or other study medication

Specific exclusion criteria for women:

  • Pregnant or breast-feeding woman.
  • Woman of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception (i.e. hormonal contraceptives, intra-uterine device, contraceptive implant or condoms with spermicide)

Exclusion criteria

related to general conditions

  • Inability of patient to understand the investigation procedures and thus inability to give valid, informed consent.
  • Non-compliant patient (e.g. not willing to attend the follow-up visits, way of life interfering with compliance)
  • Participation in another clinical study or clinical investigation at the same time as the present investigation
  • Participation to the present clinical investigation during the exclusion period of another clinical study
  • Patient already included once in this clinical investigation
  • Patient under guardianship

Treatment and study plan

Cyclosporin

Drug

This medicinal product contains cyclosporine 0.1% as an active ingredient and pefluorobutylpentane as vehicle.

Primary outcomes

  1. Dryness score assessed by a VAS and Conjunctival hyperemia grading with Photographs (Efron) scale at week 12

    Time frame: at week 12 versus baseline

    Scores will be determined using a 100 mm VAS on which 0 means "no feeling of eye dryness" and 100 means "most imaginable feeling of eye dryness".

Sponsors and collaborators

Lead sponsor

Laboratoires Thea

Industry

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Nov 18, 2025
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.